Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · see citing works

Glucagon-like peptide-1: a potent regulator of food intake in humans

Gutzwiller, J.-P., Göke, B., Drewe, J., Hildebrand, P., Ketterer, S., Handschin, D., Winterhalder, R., Conen, D., & Beglinger, C. (1999) · Gut · doi:10.1136/gut.44.1.81 · Cited by 571 · see citing works

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · see citing works

Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide

Deacon, C. F., Nauck, M. A., Meier, J. J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 439 · see citing works

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1× · see citing works

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.

D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309 · see citing works

Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects

Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300 · see citing works

Prolyl peptidases: a serine protease subfamily with high potential for drug discovery

Rosenblum, J. S., & Kozarich, J. W. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00084-x · Cited by 284 · see citing works

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265 · see citing works

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins

Vaag, A. A., Holst, J. J., Vølund, A., & Beck‐Nielsen, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350425 · Cited by 154 · see citing works

The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.

Augustyns, K., Bal, G., Thonus, G., Belyaev, A., Zhang, X. M., Bollaert, W., Lambeir, A., Durinx, C., Goossens, F. J., & Haemers, A. (1999) · PubMed · Cited by 131 · see citing works

The Unique Properties of Dipeptidyl-peptidase IV (DPP IV I CD26) and the Therapeutic Potential of DPP IV Inhibitors

Augustyns, K., Bala, G., Thonusa, G., Belyaeva, A., Zhanga, X. M., Bollaerta, W., Lambeirb, A. M., Durinxb, C., Goossensb, F., & Haemersa, A. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220208213543 · Cited by 125 · see citing works

Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106 · see citing works

Effect of ageing and diabetes on glucose‐dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose

Meneilly, G. S., Demuth, H. U., McIntosh, C. H. S., & Pederson, R. A. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00236.x · Cited by 81 · see citing works

Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells

Pala, L., Mannucci, E., Pezzatini, A., Ciani, S., Sardi, J., Raimondi, L., Ognibene, A., Cappadona, A., Vannelli, B., & Rotella, C. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.111 · Cited by 76 · see citing works

The Inhibitory Effect of Glucagon-Like Peptide-1 (7-36)amide on Antral Motility is Antagonized by Its N-Terminally Truncated Primary Metabolite GLP-1 (9-36)amide

Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · Peptides · doi:10.1016/s0196-9781(98)00020-5 · Cited by 68 · see citing works

Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters

Durinx, C., Neels, H. M., der Auwera, J.-C. V., Naelaerts, K., Scharpé, S., & Meester, I. D. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.026 · Cited by 62 · see citing works

Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance

Mannucci, E., Ognibene, A., Sposato, I., Brogi, M., Gallori, G., Bardini, G., Cremasco, F., Messeri, G., & Rotella, C. M. (2003) · Acta Diabetologica · doi:10.1007/s00592-003-0109-8 · Cited by 61 · see citing works

Effect of Nutrient Ingestion on Glucagon-Like Peptide 1 (7-36 Amide) Secretion in Human Type 1 and Type 2 Diabetes

Lugari, R., Dell’Anna, C., Ugolotti, D., Dei, A., Barilli, A., Zandomeneghi, R., Marani, B., Iotti, M., Orlandini, A., & GNUDI, A. (2000) · Hormone and Metabolic Research · doi:10.1055/s-2007-978665 · Cited by 60 · see citing works

Incretin hormone expression in the gut of diabetic mice and rats

Berghöfer, P., Peterson, R. G., Schneider, K., Fehmann, H. C., & Göke, B. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90251-1 · Cited by 37 · see citing works

Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin (9–39)

Green, B., Mooney, M., Gault, V. A., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2004) · Metabolism · doi:10.1016/j.metabol.2003.09.015 · Cited by 33 · see citing works

Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema

Byrd, J. B., Touzin, K., Sile, S., Gainer, J. V., Yu, C., Nadeau, J., Adam, A., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.096552 · Cited by 147 · see citing works

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121 · see citing works

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99 · see citing works

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63 · see citing works

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV

Marchetti, C., Di Carlo, A., Facchiano, F., Senatore, C., De Cristofaro, R., Luzi, A., Federici, M., Romani, M., Napolitano, M., Capogrossi, M. C., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2213-6 · Cited by 52 · see citing works

Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor–induced peritracheal edema

Byrd, J. B., Shreevatsa, A., Putlur, P., Foretia, D., McAlexander, L., Sinha, T., Does, M. D., & Brown, N. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.012 · Cited by 52 · see citing works

Incretin drugs as modulators of atherosclerosis

Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35 · see citing works

Association of variants near the bradykinin receptor B2 gene with angioedema in patients taking ACE inhibitors

Ghouse, J., Ahlberg, G., Andreasen, L., Banasik, K., Brunak, S., Schwinn, M., Larsen, I. H., Petersen, O., Sørensen, E., Ullum, H., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.054 · Cited by 24 · see citing works

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome

Suman, R. K., Borde, M. K., Mohanty, I. R., & Singh, H. K. (2023) · International Journal of Applied & Basic Medical Research · doi:10.4103/ijabmr.ijabmr_115_23 · Cited by 7 · see citing works

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

Reimer, M. K., Holst, J. J., & Åhrén, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 196 · see citing works

Eficácia dos inibidores da dipeptidil peptidase 4 (DPP-4) para o tratamento da diabetes mellitus 2 / Efficacy of dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus

Rocha, K. N. S., Pereira, B. M., Costa, I. L., Fabri, G. G., Wilhans, C. N., Lemos, L. F., Machado, M. R. R., & Rodrigues, M. S. D. L. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n1-026 · Cited by 1 · see citing works

Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats

Kirino, Y., Sato, Y., Kamimoto, T., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00319.2010 · Cited by 32 · see citing works

Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats.

Kirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., Minakuchi, K., & Nakahori, Y. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0424 · Cited by 88 · see citing works

Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3–42) and GLP-1(9–36)amide, on insulin secretion and glucose homeostasis in ob/ob mice

Parker, J. C., Lavery, K. S., Irwin, N., Green, B., Greer, B., Harriott, P., O'Harte, F. P. M., Gault, V. A., & Flatt, P. R. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06904 · Cited by 18 · see citing works